NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Часто задаваемые вопросы
В каком секторе работает Neuropace Inc (NPCE)?
Neuropace Inc относится к сектору Здравоохранение.
Какова текущая цена акций Neuropace Inc (NPCE)?
По последним данным, цена акций Neuropace Inc составляет 13,14 $, предыдущее закрытие — 13,05 $. За последнюю торговую сессию акции Neuropace Inc выросли на 0,09 $, что соответствует росту на 0,69%.
Выплачивает ли Neuropace Inc (NPCE) дивиденды?
Нет, Neuropace Inc не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Neuropace Inc (NPCE)?
У компании Neuropace Inc бета 1.937, что указывает на повышенную волатильность по сравнению с рынком.